{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T20:07:58Z","timestamp":1772309278573,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1136\/annrheumdis-2016-209429","type":"journal-article","created":{"date-parts":[[2016,4,2]],"date-time":"2016-04-02T02:43:34Z","timestamp":1459565014000},"page":"1268-1271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8899-9087","authenticated-orcid":false,"given":"Josef S","family":"Smolen","sequence":"first","affiliation":[]},{"given":"Sabine","family":"Collaud Basset","sequence":"additional","affiliation":[]},{"given":"Maarten","family":"Boers","sequence":"additional","affiliation":[]},{"given":"Ferdinand","family":"Breedveld","sequence":"additional","affiliation":[]},{"given":"Christopher J","family":"Edwards","sequence":"additional","affiliation":[]},{"given":"Tore K","family":"Kvien","sequence":"additional","affiliation":[]},{"given":"Pierre","family":"Miossec","sequence":"additional","affiliation":[]},{"given":"Tuulikki","family":"Sokka-Isler","sequence":"additional","affiliation":[]},{"given":"Ronald F","family":"van Vollenhoven","sequence":"additional","affiliation":[]},{"given":"Eric C","family":"Abadie","sequence":"additional","affiliation":[]},{"given":"Olivier","family":"Bruy\u00e8re","sequence":"additional","affiliation":[]},{"given":"Cyrus","family":"Cooper","sequence":"additional","affiliation":[]},{"given":"Heidi","family":"M\u00e4kinen","sequence":"additional","affiliation":[]},{"given":"Thierry","family":"Thomas","sequence":"additional","affiliation":[]},{"given":"Peter","family":"Tugwell","sequence":"additional","affiliation":[]},{"given":"Jean-Yves","family":"Reginster","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1136\/annrheumdis-2016-209429_bib1","unstructured":"European Agency for the Evaluation of Medicinal Products. Guideline on clinical investigation of medicinal products other than NSAIDs for treatment of rheumatoid arthritis. 20 March 2015. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2015\/06\/WC500187583.pdf (accessed 22 Jan 2016)."},{"key":"10.1136\/annrheumdis-2016-209429_bib2","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1093\/rheumatology\/keq413","article-title":"Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis","volume":"50","author":"Smolen","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2016-209429_bib3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1185\/03007995.2010.542135","article-title":"Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA","volume":"27","author":"Smolen","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1136\/annrheumdis-2016-209429_bib4","unstructured":"European Agency for the Evaluation of Medicinal Products. Points to consider on clinical investigation of medicinal products other than NSAIDs for treatment of rheumatoid arthritis. 17 December 2003. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003439.pdf (accessed 22 Jan 2016)."},{"key":"10.1136\/annrheumdis-2016-209429_bib5","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-209429_bib6","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/ard.2011.149765","article-title":"American College of Rheumatology\/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"70","author":"Felson","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-209429_bib7","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-209429_bib8","unstructured":"European Medicines Agency. Concept paper on the need for revision of the points to consider on the clinical investigation of medicinal products other than NSAIDS in rheumatoid arthritis (CPMP\/EWP\/556\/95 REV. 1). 20 January 2010. http:\/\/trbmossge:8801\/sites\/scientifique\/Docs\/Documents\/E\/Conceptpaperneedrevision.pdf (accessed 22 Jan 2016)."},{"key":"10.1136\/annrheumdis-2016-209429_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/annrheumdis-2016-209429_bib10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/ard.2005.044354","article-title":"EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"66","author":"Combe","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-209429_bib11","first-page":"835","article-title":"Whither the ACR20?","volume":"31","author":"Felson","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2016-209429_bib12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/ar4428","article-title":"The ACR20 and defining a threshold for response in rheumatic diseases: too much of a good thing","volume":"16","author":"Felson","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/annrheumdis-2016-209429_bib13","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1002\/art.27711","article-title":"Non-overlapping American College of Rheumatology response rates: a better way to report response in rheumatoid arthritis clinical trials","volume":"62","author":"Boers","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2016-209429_bib14","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/annrheumdis-2012-201491","article-title":"Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index","volume":"71","author":"Aletaha","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-209429_bib15","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1136\/ard.2004.034371","article-title":"Comparison of different definitions to classify remission and sustained remission: 1\u2005year TEMPO results","volume":"64","author":"van der Heijde","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-209429_bib16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/annrheumdis-2011-201247","article-title":"Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study","volume":"72","author":"Kavanaugh","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-209429_bib17","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.21235","article-title":"Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states","volume":"52","author":"Aletaha","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2016-209429_bib18","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/ard.2005.037333","article-title":"Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?","volume":"64","author":"M\u00e4kinen","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 3","key":"10.1136\/annrheumdis-2016-209429_bib19","doi-asserted-by":"crossref","first-page":"iii56","DOI":"10.1136\/ard.2007.078360","article-title":"Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility","volume":"66","author":"Bakker","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-209429_bib20","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2016-209429_bib21","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-209429_bib22","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2016-209429_bib23","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/annrheumdis-2015-207628","article-title":"Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial","volume":"75","author":"Burmester","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-209429_bib24","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1136\/annrheumdis-2016-209429_bib25","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2016-209429_bib26","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"issue":"Suppl 10","key":"10.1136\/annrheumdis-2016-209429_bib27","first-page":"S334","article-title":"Remission rates with tofacitinib treatment in rheumatoid arthritis: a comparison of various remission criteria","volume":"64","author":"Smolen","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2016-209429_bib28","doi-asserted-by":"crossref","first-page":"R796","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score","volume":"7","author":"Aletaha","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/annrheumdis-2016-209429_bib29","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/acr.20481","volume":"63","author":"Pincus","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/annrheumdis-2016-209429_bib30","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1002\/art.39322","article-title":"A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol","volume":"67","author":"Curtis","year":"2015","journal-title":"Arthritis Rheumatol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724017801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724017801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/annrheumdis-2016-209429","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T08:27:57Z","timestamp":1739521677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724017801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0003496724017801"],"URL":"https:\/\/doi.org\/10.1136\/annrheumdis-2016-209429","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2016-209429","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}